Cargando…

SARS-CoV-2 vaccination in IBD: more pros than cons

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Amico, Ferdinando, Rabaud, Christian, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816748/ https://www.ncbi.nlm.nih.gov/pubmed/33473178 http://dx.doi.org/10.1038/s41575-021-00420-w

Ejemplares similares

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

The day after COVID-19 in IBD: how to go back to ‘normal’
por: Danese, Silvio, et al.
Publicado: (2020)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience
por: Furfaro, Federica, et al.
Publicado: (2020)

Management of IBD during the COVID-19 outbreak: resetting clinical priorities
por: Danese, Silvio, et al.
Publicado: (2020)

Rectal retractor in prostate radiotherapy: pros and cons
por: Ghaffari, Hamed, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Fluids in ARDS: more pros than cons
por: Mendes, Renata de S., et al.
Publicado: (2020)

Blockchain for Electronic Vaccine Certificates: More Cons Than Pros?
por: Toubiana, Raphaëlle, et al.
Publicado: (2022)

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

SARS-CoV-2 seroprevalence in healthcare workers and risk factors
por: Weber, Stéphanie, et al.
Publicado: (2022)

Routine use of indirect calorimetry in critically ill patients: pros and cons
por: De Waele, Elisabeth, et al.
Publicado: (2022)

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021)

B cells: more than just for antibodies in SARS-CoV-2 vaccine responses
por: Paley, Michael A, et al.
Publicado: (2021)

Moving towards more patient-centred clinical trials in IBD
por: Noor, Nurulamin M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_18gnjsstc3fl4f7c3qasf0f7ng